Retrospective study shows similar gvhd rates but delayed engraftment with post transplant cyclophosphamide in myelofibrosis patients.
Key Points
To evaluate the safety and efficacy of post transplant cyclophosphamide versus tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis patients.
Retrospective analysis of myelofibrosis patients undergoing allo-HCT at Mayo Clinic after 2016.
Compared safety and efficacy of PTCy-based regimens to tacrolimus plus methotrexate.
Analyzed overall survival, progression-free survival, acute and chronic GVHD incidence, and engraftment times.
PTCy demonstrated similar rates of grade ≥2 acute and moderate-severe chronic GVHD compared to tacrolimus and methotrexate.
Engraftment was significantly delayed in the PTCy group for neutrophils and platelets.
Median overall survival for PTCy was 72.8 months, while for non-PTCy it was 93.4 months, showing no significant difference.